Shanghai Pharmaceuticals Holding Stock Price To Earnings To Growth
| 601607 Stock | 21.93 0.51 2.38% |
Shanghai Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Shanghai Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Pharmaceuticals stock.
Shanghai | Price To Earnings To Growth |
Shanghai Pharmaceuticals Holding Company Price To Earnings To Growth Analysis
Shanghai Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Shanghai Pharmaceuticals Price To Earnings To Growth | 10.62 X |
Most of Shanghai Pharmaceuticals' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Shanghai Pharmaceuticals Holding has a Price To Earnings To Growth of 10.6199 times. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The price to earnings to growth for all China stocks is notably lower than that of the firm.
Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Shanghai Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Shanghai Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Shanghai Pharmaceuticals' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Shanghai Fundamentals
| Return On Equity | 0.0641 | ||||
| Return On Asset | 0.0241 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 80.19 B | ||||
| Shares Outstanding | 2.79 B | ||||
| Shares Owned By Insiders | 65.61 % | ||||
| Shares Owned By Institutions | 13.26 % | ||||
| Price To Book | 1.15 X | ||||
| Price To Sales | 0.27 X | ||||
| Revenue | 260.3 B | ||||
| Gross Profit | 28.41 B | ||||
| EBITDA | 9.62 B | ||||
| Net Income | 3.77 B | ||||
| Total Debt | 35.56 B | ||||
| Book Value Per Share | 19.13 X | ||||
| Cash Flow From Operations | 5.23 B | ||||
| Earnings Per Share | 1.08 X | ||||
| Price To Earnings To Growth | 10.62 X | ||||
| Target Price | 21.44 | ||||
| Number Of Employees | 48.16 K | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 72.7 B | ||||
| Total Asset | 211.97 B | ||||
| Retained Earnings | 33.82 B | ||||
| Working Capital | 40.06 B | ||||
| Net Asset | 211.97 B | ||||
| Last Dividend Paid | 0.41 |
About Shanghai Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.